INTRODUCTION
Prescription drug management plans are outpatient drug benefit programs that strive to manage the cost effective and clin ically appropriate delivery of prescription drugs to beneficiaries through a range of services. These services are provided on behalf of managed care organizations (MCOs), employers, third-party payers and may encompass a variety of activities.
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They may be delivered by a distinct orga nization such as a pharmacy benefit man agement company (PBM), a unit within an MCO or an integrated delivery system.
The demand for accountability and a means to evaluate performance of drug benefit management programs is growing. Nevertheless, a set of valid, standardized indicators for evaluating prescription drug management does not currently exist (Lipton et al., 1999) . In its assessment of health maintenance organization (HMO) relationships and experiences with PBMs, the Office of the Inspector General (OIG) concluded that more oversight of PBM performance is warranted. It recommend ed that HCFA and State Medicaid agencies pursue actions to ensure that their HMOs are accountable for the quality of PBM ser vices delivered to beneficiaries (U.S. Office of the Inspector General, 1997). OIG also recommended that Federal agencies, with other public and private organizations, pur sue efforts to support the development of standards and measures for evaluating the quality of care for pharmacy services in the context of managed care. Suggestions about strategies for making PBMs more accountable to employers have also been put forth (Schulman et al., 1996) .
This article reviews the functions of pre scription drug management programs and discusses currently available performance measures that may be used to assess drug management activities. Issues related to reporting requirement implementation are also raised. We also note recent efforts to develop valid, standardized indicators for evaluating drug management programs. We conclude by asking three key ques tions that must be addressed before a com prehensive set of performance measures for prescription drug management programs is fully implemented.
WHY MEASURE PERFORMANCE?
Over the last decade, prescription drug spending has generally received considerable scrutiny due to its growth rate and share of national health expenditures (Levit et al., 2000) . Growth rates increased from 8.7 percent in 1993 to 15.4 percent in 1998. Spending for prescription drugs increased from 6 percent of health spending in 1994 to 8 percent in 1998. Moreover, prescrip tion drug spending represented a 20-percent share of the increase in health spend ing in 1998. The desire to understand the impact of prescription drug management on prescribing behavior, drug utilization, and spending has grown commensurately.
PBMs and entities that provide drug man agement services have become key organi zations in the provision of prescription drugs. A recent survey of HMOs revealed that 600 of 604 HMOs had a drug benefit; only 57 HMOs of the 600 with a drug bene fit did not provide prescription drug coverage through a PBM (Pharmacy Benefit Management Institute, Inc., 2000) . Based on these figures, the Pharmacy Benefit Management Institute has estimated PBM coverage to be approximately 160-190 million individuals in the U.S. (Pharmacy Benefit Management Institute Inc., 2000) .
The large percentage of HMOs delegating the management of their prescription drug services to outside entities has increased interest in holding those organizations accountable. To date, most HMOs have focused efforts on measuring the net financial benefit of delegating this activity. However, interest in measuring the quality of the ser vices provided has increased. Concern about pharmaceutical company ownership of pre scription drug management companies and strategic alliances and partnerships with them has also contributed to interest in PBM activities (U.S. General Accounting Office, 1995) . In its study of HMOs and PBMs, the OIG found that HMOs cited the potential impact of PBM alliances with drug manufac turers to be an important issue (U.S. Office of the Inspector General, 1997). OIG noted four areas in which PBM behavior could be affect ed: (1) formularies, (2) drug use review programs, (3) educational interventions, and (4) cost-effectiveness research. With the sale of Diversified Pharmaceutical Services by SmithKline Beecham and PCS Health Systems by Eli Lilly and Company within the last 5 years, Merck-Medco is the only PBM owned by a pharmaceutical company. Nevertheless, strategic alliances and partnerships remain.
The scope of prescription drug manage ment activities may range from administra tive and management functions (e.g., claims processing and adjudication, phar macy network management) to clinical activities (e.g., formulary development and management) and cost containment func tions (e.g., rebate negotiation and contract ing with pharmaceutical manufacturers) (Kreling et al., 1996) . This broad array of activities may encompass complex financial incentives and include control over drug utilization; consequently, there is interest in understanding the impact of drug manage ment systems on quality of care as well on prescription drug expenditures.
The role that PBMs play in managing drug benefits may grow if the Medicare program is expanded to include outpatient prescription drug benefits. Several pro posals for Medicare drug benefits advocate adopting private-sector strategies where PBMs administer outpatient prescription drug coverage (McClellan, Spatz, and Carney, 2000; Huskamp et al., 2000; Etheredge, 1999) . A recent evaluation of the potential contribution of PBMs in extending Medicare benefits to outpatient prescription drugs identified advantages, limitations, and operational challenges (Cook, Kornfield, and Gold, 2000) . The five sets of operational issues that would need to be addressed include: (1) the use of for mularies, (2) the competitive bidding process, (3) access to discounted prices, (4) beneficiary cost sharing, and (5) edu cation. Performance measurement data for drug benefit programs would support informed decisionmaking in these areas. Another recent study looked at drug use management strategies in four large Medicare HMOs to assess the potential impact of prescription drug management plans for the Medicare program (Lipton et al., 2000) . This study also highlighted sev eral areas related to drug management activities that require further investigation.
PRESCRIPTION DRUG MANAGEMENT PROGRAMS
The structure and contractual relationships of prescription drug management programs have been well documented (Lipton et al., 1999) . Lipton and colleagues describe a continuum of contractual rela tionships that ranges from a "carved-in" program to a "carved-out" program. In the carved-in arrangement, prescription drug management programs reside within a larg er organization, and there is no contractual relationship with a separate organization. An intermediate arrangement has been characterized as a subcontractual or part nership relationship. In this type of struc ture, some drug management activities may be performed by the health plan or all drug management activities are performed for a health plan by a PBM through a subcontract. A carved-out relationship repre sents a true contractual relationship in which a purchaser, such as an employer, contracts separately with a PBM to manage its prescription drug benefit.
The activities in which prescription drug management programs may engage have been described and classified in a number of different ways, including evolution in ser vice mix (Schulman et al., 1996) , the degree of impact on patient care (U.S. Office of the Inspector General, 1997), and the function al similarity of activities (Kreling et al., 1996; Lipton et al., 1999) . Our framework for discussing performance measurement for prescription drug management programs builds on these classification schemes, and we suggest that four major categories of drug benefit management activities should be considered, as illustrat ed in Table 1 : (1) administrative and man agement, (2) drug use control, (3) cost con tainment, and (4) disease management. These functions are described in further detail in the following section. 
AVAILABLE MEASURES AND CHALLENGES FOR IMPLEMENTATION
Current tools for monitoring and improving prescription drug use are frag mented and not standardized. The litera ture indicates that the selection of mea sures reported is discretionary and varies across organizations.
Consequently, MCOs and purchasers often have incom plete information to assess the value of pre scription drug management programs.
In the following sections, we suggest a basic framework for conducting perfor mance measurement activities using available measures. For each of four major cat egories of activities, we review existing pharmaceutical care performance mea sures, describe the data required to calcu late them, and describe any feasibility issues associated with that calculation.
Performance Measurement Using Currently Available Measures

Administrative and Management Activities
Indicators to measure administrative and management activities can be orga nized into the following subcategories: claims processing, pharmacy network management, and utilization management.
Claims processing is a core function drug management programs offer to MCOs and purchasers, and therefore its effectiveness should be measured. As indi cated in Table 2 such measures are similar to those commonly used to evaluate the administrative functions of MCOs. A mea surement set should include the average time required to process claims, along with claims "aging" measures, such as the num ber of backlogged claims and a distribution measurement of the length of the backlog. In addition, overall claims processing accu racy percentages should be evaluated. The data for these measures can be obtained by requiring the PBM or drug management program to report the measures or through an independent audit of the claims process ing function conducted by the MCO, pur chaser, or a third party. The number of complaints associated with claims process ing also can be evaluated to assess trends in payment accuracy or timeliness. An MCO or purchaser typically will assess whether an adequate network of pharmacies has been developed. Network adequacy is reflected in beneficiary access, which may be measured by the percentage of pharma cies in a certain region, pharmacy provider turnover, and average time required to process a prescription. In assessing average time required to process a prescription, mail order and retail pharmacy services should be considered separately. Averaging the processing time for the two delivery meth- ods would not produce meaningful results because retail delivery has a much shorter turnaround time. As with claims processing, purchasers and MCOs can require PBMs to report on these functions. The access mea sures also may be evaluated using the PBM pharmacy directory and comparing it with membership demographic information. Patient satisfaction with the pharmacy network may be measured through a satisfac tion survey, too. The most widely used standard measure of prescription drug utilization is the outpatient drug utilization measure included in the Health Plan Employer Data and Information Set (HEDIS ® ) maintained by the National Committee for Quality Assurance (NCQA) (National Committee for Quality Assurance, 2000b) . This measure includes several com ponents, including the total number of pre scriptions and the average number of pre scriptions per member per year, stratified by age group. The utility of this measure, par ticularly for comparisons across populations, is limited by the lack of risk adjustment for population differences in sex and health sta tus. An additional measure of utilization, which is not included in the outpatient drug utilization measure, is average days supply dispensed. When implementing this mea sure, mail-order prescriptions (where the quantity is frequently large) and retail-filled prescriptions must be distinguished. A more comprehensive review of utilization can be obtained by looking at the distribution of claims across therapeutic class, within thera peutic groups, and by investigating the uti lization and cost drivers of expenditure growth (Dubois et al., 2000) . Comprehensive approaches to measuring utilization require linking pharmacy claims with medical claims.
Drug Use Control Activities
Drug use control covers a number of drug management functions, including for mulary management, drug mix and interchange programs, and drug utilization review processes. Measures that can be used to assess these activities are summa rized in Table 3 . A large component of pre scription drug management activities are centered on developing and managing the formular y.
Although employers and MCOs determine how restrictive the for mulary is (open, preferred, or closed), the Pharmacy and Therapeutics Committee of the PBM or MCO determines the actual drugs that are included on the list. Both the frequency with which the formulary is reviewed and updated, and the structure of the Pharmacy and Therapeutics Committee are items that MCOs must monitor for NCQA accreditation (National Committee for Quality Assurance, 2000a).
Drug management programs, in addition to purchasers, are interested in measuring physician and pharmacy compliance with 
Cost Containment
Monitoring the costs and savings of drug management programs has been the main focus of performance measurement to date. Cost containment is the activity with the largest number of currently available performance measures, although there are not any published standards on how drug management programs should calculate and report these measures to purchasers. The absence of standardized methods for such calculations makes it dif ficult to compare the relative effectiveness of drug management programs. Measures that may be used to assess cost contain ment are presented in Table 4 .
There are standard specifications for cal culating total cost of prescriptions and average cost of prescriptions per member, per year in the HEDIS ® measure for outpa tient drug utilization. These measures are calculated using pharmacy claims and enrollment data. Both measures would provide a clearer picture of cost issues if eval uated separately by therapeutic class.
Information on rebates and discounts pro vides detail on the savings associated with a PBM that negotiates arrangements with pharmaceutical manufacturers. However, detailed data on rebates and discounts can be difficult to obtain because PBMs general ly consider the data to be proprietary.
While drug utilization review (DUR) occurs both prospectively and retrospec tively on an ongoing basis at MCOs and PBMs, there are few performance mea sures available to quantify the impact of DUR programs. The most commonly used measure is DUR savings per member per month or per claim. When evaluating DUR activity, the costs of the administration of the DUR program should be included in any cost-benefit calculation. In some cases, complete cost information may not be provided when a drug management program submits reports on DUR activity. 
Disease Management
Disease management programs have been created as drug management programs have found that patients with cer tain chronic conditions may benefit from further intervention. Disease manage ment programs have a clinical focus; con sequently, we consider them separately from drug use control activities. To mea sure the impact of disease management interventions, it is necessary to link the information contained in patient medical claims and encounters with pharmacy claims and encounters. Further work is needed in developing measures that better assess outcomes of care rather than process of care. True outcome measures address success and failure rates for thera py and the avoidance of certain health events, such as emergency room admis sions and clinical complications (e.g., amputations in diabetics, infections after surgery). Measures that are useful in assessing disease management activities are summarized in Table 5 .
Combining medical claims data with information obtained from DUR assess ments can provide valuable information on the impact of disease management programs and education efforts. Another measurement that should be considered is the outcome associated with the underuse of drugs that have been identified as high ly effective for persons with certain condi tions. Education related measures, such as patient medication adherence and physi cian prescribing compliance for conditions in which under utilization of pharmaceuti cal care is often an issue (i.e., asthma, depression, cholesterol management), can be measured by linking pharmacy and medical claims. In addition, adverse drug events per thousand patients provide a measurement of prescription drug interac tion monitoring activities.
Findings from outcomes research stud ies on cost offset and cost effectiveness can be used to evaluate pharmaceutical treatments embodied in disease manage ment activities (Grabowski and Mullins, 1997) . Findings from these types of stud ies are also used in making formulary deci sions (Grabowski and Mullins, 1997; Luce, Lyles, and Rentz, 1996) . These types of studies may include cost-offset and costeffectiveness studies, cost-benefit, cost-util ity and cost of illness analysis.
The measures in the Effectiveness of Care domain of HEDIS ® focus on the clini cal quality of care delivered by an MCO. These measures assess levels of preven tive care (i.e., breast and cervical cancer screenings and vaccinations), treatments for those with acute episodes of illness, and care for those with chronic disease. Three HEDIS ® 2001 measures in the Effectiveness of Care domain specifically integrate medical event with pharmaceutical use information to assess quality of care for services often targeted for disease management programs. These measures are: beta blocker treatment after a heart attack, antidepres sant medication management, and appro priate medications for people with asthma. More work is needed in developing dis ease management performance measures. NCQA is in the process of developing a dis ease management certification program that would encompass services provided by stand-alone vendors, pharmaceutical com panies, PBMs with disease management services, internet-based disease manage ment companies, health plans, and other health providers (hospitals, medical groups, etc.). Expected to be operational by the end of 2001, the program will include modification of existing HEDIS ® measures and the possible development of new ones for disease management programs.
Beneficiary Satisfaction
Similar to the Agency for Health Care Policy and Research's Consumer Assessment of Health Plan Study (CAHPS ® ) survey used for HEDIS ® , a pharmacy benefits satisfac tion survey could be implemented in a drug management program comprehen sive measure set. A PBM satisfaction sur vey would measure how effectively an PBM performs its core functions of admin istration and management, drug use con trol, disease management, and cost con tainment. Many of the existing CAHPS ® survey questions can be slightly modified to apply to PBM services, such as claims processing, customer service, and receiv ing care quickly. A PBM satisfaction sur vey should not only include an overall rat ing of the PBM, but also an overall rating of the pharmaceutical provider network. The PBM Institute has developed a customer satisfaction survey for the PBM industry that asks employers and MCOs to rate the services of their PBMs on a scale from 1 to 10. This could be used as a component of a satisfaction measurement. Building on information contained in the Response Oriented Patient Evaluation Survey tool (Silverman and Rosen, 1999) , pharmacy specific measures should also be included in the satisfaction survey. Appropriate questions could include (1) patient's access to pharmacies in the PBM network, (2) their satisfaction with the pharmacy's ability to fill their prescriptions appropri ately, (3) whether the pharmacist has pro vided appropriate counseling and advice, and (4) whether the price of the prescribed medication was competitive. Additionally, questions on satisfaction with pharmaceu tical care from the Foundation for Accountability's (FACCT) Annual Patient Satisfaction Survey could be incorporated. Potential satisfaction measures are sum marized in Table 6 .
Technical Challenges in Performance Measurement
Technical challenges in performance measurement include data timeliness, data accuracy, data completeness, and database linkage issues. Before a comprehensive measurement tool for prescription drug management systems can be developed these factors must be considered. The timely availability of the required data ele ments for any individual measure can influ ence whether that measure is included in a purchaser's or MCO's measurement set. Furthermore, the measurement focus of purchasers and MCOs can be greatly influ enced by an organization's contractual rela tionship with a PBM. Because organiza tions frequently delegate data processing and claims payment directly to an PBM, the timeliness of data provided may be determined by that contract or by the PBM.
Timeliness can also be influenced by whether a prescription drug management system collects data at the point of service delivery. Data collection at the point of delivery facilitates access to data on a realtime basis with no need to wait for the submission of a paper claim form. Organizations which receive most of their information on paper claims will have a longer time lag and consequently may not be able to supply updated data promptly. Additional issues of timeliness occur when pharmacy claims must be linked with med ical claims to produce a measure, and the submission and processing of the medical claims contributes to delays in accessing required information.
It is critical to evaluate data accuracy and determine data issues affecting particular measures. Data collected electronically at the point of sale is less prone to error. This data is captured only once, does not need to be rekeyed, and is entered by the origi nal provider of ser vice, increasing its chances of accuracy. Data submitted via paper claims is documented by the provider of service but then must be entered into the MCO's data processing system by hand, possibly resulting in errors. Common data errors for both types of data include incorrect patient iden tification, incorrect prescriber identifica tion, incorrect date of service, and invalid or incorrect drug code. To screen out these errors, prescription drug manage ment systems should be using edit checks prior to accepting a claim for processing.
Data completeness is affected by the contracting arrangement between a pre scription drug management plan and an MCO. Which data elements collected and retained during processing and payment often are determined by the PBM, rather than the MCO or purchaser. In some cases, the PBM may not be capturing all of the data elements needed to conduct per formance measurement. The ability to specify which data elements are retained and provided for analysis and measure ment is a key issue for contracting arrangements with a prescription drug management plan. MCOs and purchasers who realize that they need additional data elements often discover that they cannot request them until it is time to recontract, which could be a year later. Additionally, not all prescription drugs used by plan members may not be captured in the phar maceutical benefit data system. For exam ple, physicians often provide medication samples to their patients that are not cap tured in data systems and some patients may opt to pay for their pharmaceuticals out of pocket, rendering the prescription drug history incomplete.
A number of key fields that a purchaser or MCO might want for performance mea surement are not standard fields included in the typical prescription drug manage ment system database. They would need to be obtained from claims and encounter data, another source of administrative data, or medical records. These data elements include patient diagnosis information, place of service, and information linking the particular prescription to a hospital stay or surgical procedure. MCOs and pur-chasers often treat the PBM data as a sep arate database; therefore, organizations conducting performance measurement face a technical challenge in merging files to obtain a complete picture of experience for a particular patient. Challenges include file format compatibility, a common patient identifier used for linking, the potential for duplicate records, the consistency of other data elements, and efficiently handling extremely large files containing pharmacy data. The availability of this information greatly influences the MCO's or purchas er's ability to conduct comprehensive per formance measurement of all PBM func tions.
PERFORMANCE MEASUREMENT DEVELOPMENT EFFORTS
A variety of entities have sponsored the development of measures to evaluate phar maceutical care. To date, however, no one entity has defined a comprehensive set of pharmaceutical performance measures that meet the quality of care, financial, outcomes, and satisfaction information needs of purchasing groups (MCOs, govern ments, employers, and other purchasers), policymakers, and consumers. In this sec tion, we review performance measurement development efforts by various organiza tions.
Healthcare Quality Organizations
In recent years, groups such as the NCQA and the Joint Commission on the Accreditation of Health Care Organizations (JCAHO) have challenged health and MCOs to use data from their pharmacy benefit programs to measure the quality and the outcome of care being provided. In the late 1990s, NCQA developed HEDIS ® as a standardized mechanism for MCOs to report performance measures to purchaser organizations and consumers. HEDIS ® measures are reported on an annual basis by MCOs. HEDIS ® is the most widely used set of performance mea sures in the managed care industry and has become a model for emerging systems of performance measurement in other areas of health care delivery (National Committee for Quality Assurance, 1999) .
Early versions of HEDIS ® did not focus on the use of medication or pharmacy ser vices. While there are still no pharmacy or PBM-specific indicators for HEDIS ® , there now are measures that assess the use of medication for specific patient populations as well as measures that quantify outpa tient drug utilization at an MCO level. Additionally, the introduction of a disease management certification program by NCQA may result in the development of performance measures for services provid ed by pharmaceutical benefit management programs.
As part of its accrediting activities, in the late 1990s, JCAHO initiated ORYX ™ , a per formance reporting initiative for health care organizations. ORYX ™ measures are devel oped by external organizations and certified by JCAHO for use by health care organiza tions seeking accreditation. As of April 2001, JCAHO's Web site listed more than 200 mea surement systems available from which health care entities may select ORYX ™ mea sures (Joint Commission on the Accreditation of Health Care Organizations, 2001). The total number of measures for which organi zations currently are required to collect and report data to JCAHO has been capped at six. There are several ORYX ™ measures that assess medication usage during inpatient and outpatient surgical procedures (e.g., anesthesia), drug use monitoring, and extent of adverse drug reactions. The majority of these measures relate to pharmacy services provided by hospitals, long-term care facili ties, and ambulatory clinics.
A number of other organizations have addressed uniform pharmaceutical perfor mance standards. FACCT, a coalition of consumer organizations and purchasers, was formed to measure health care quality and communicate results in a way that makes sense to consumers. FACCT has developed a series of quality measurement tools that are focused on outcomes for high-cost, high-prevalence diseases such as asthma, coronar y arter y disease, depression, breast cancer, diabetes melli tus, alcoholism, and smoking. FACCT's annual patient survey includes 27 ques tions on medication compliance. At this time, neither purchasing groups nor MCOs have implemented FACCT mea sures on a widespread basis.
Coalitions and Professional Associations
The Study of Clinically Relevant Indicators of Pharmacologic Therapy (SCRIPT) Project is the first major effort of the Coalition for Quality in Medication Use. The coalition is comprised of over 50 national, public, and private sector organi zations and was formed in 1998. Funded by HCFA, the SCRIPT Project has pro ceeded in two phases. The first phase, managed by the JCAHO, consisted of the development of a method for selection of measures including a review of existing measures for validity and applicability. An evidence-based, consensus-driven process focused the effort on cardiovascular dis eases, risk factors, and outcomes. The sec ond phase, managed by MassPRO, is char acterized by field-testing of measures relat ed to medication prescribing and compli ance, therapeutic monitoring, and docu mentation in heart failure, coronary artery disease, atrial fibrillation, hypertension, diabetes, and hyperlipidemia. The project will produce a compendium of tested mea sures for use by the coalition members.
The National Pharmaceutical Council's (NPC), Quality Initiative Group (QIG) is a consortium of representatives from 25 of the United States' largest research-based pharmaceutical companies having clinical, epidemiological, outcomes research, statis tical, and policy expertise. The purpose of the QIG is to provide high-level technical support for the industry to assess quality of care initiatives by external organiza tions. Among its recent efforts, NPC's QIG is serving as an Advisory Industry Council to the SCRIPT Steering Committee and is collaborating with NCQA to imple ment standards, measures, and policy to improve the quality of pharmaceutical care.
The American Pharmaceutical Associa tion's Foundation Quality Center is funding three teams of researchers as part of its Pharmacy Ser vice Quality: Research Initiative Grant Program. The grants support research projects that develop and test measures of quality of pharmacy services (American Pharmaceutical Association Foundation Quality Center, 1999). Current projects include the development of three new clinically significant quantitative indi cators of community pharmacy perfor mance: (1) apparent mistimed refills, (2) apparent therapeutic duplication, and (3) inappropriate length of therapy. Other pharmacy service QRI studies focus on measuring patient satisfaction with phar macy services and documenting require ments for pharmacists to assess quality.
The American Society for Automation in Pharmacy has initiated a workgroup to establish the framework for a standard pro tocol to interface disease management sys tems with pharmacy management sys-tems. The workgroup is also exploring the development of a standardized set of data elements that can serve to measure outcomes.
Facilitated by the Academy of Managed Care Pharmacy, the Pharmacy Quality Council is a cooperative effort of nine pro fessional and trade organizations that has developed an inventory of performance indicators relevant to the pharmaceutical care industry. The inventory is called the Summary of National Pharmacy Quality Measures. (Pharmacy Quality Council, 1999) . One of the council's objectives is to develop new measures for pharmacy quali ty and utilization that surpass the measures currently used throughout the Nation.
COMPREHENSIVE MEASUREMENT
With the evolution of managed care in response to demands for cost containment, purchasers of health benefits ultimately demanded accountability for the quality of care delivered. NCQA and HEDIS ® mea sures emerged in response to those demands (Iglehart, 1996) .
Similarly, efforts to control costs while delivering prescription drugs appropriately in an envi ronment of increased drug utilization and spending along with the availability of new medications to treat and prevent chronic illness will fuel demands for accountability of drug management programs. Recognizing that accountability is warranted, that drug benefit programs provide a broad array of ser vices that may have a tremendous impact on patient outcomes, and that there is a need for better information to make decisions about the design, implementa tion, and management of these programs, three key issues emerge. First, given the continuum of contractual relationships for including drug benefit programs in the menu of health benefits that are offered to beneficiaries, what organization should be accountable for the activities of a drug ben efit program? Second, what should be the content of a comprehensive set of stan dardized performance measures for pre scription drug management programs? Third, what organization or coalition will ultimately be vested with the responsibility of developing a comprehensive set of per formance measures for drug benefit programs?
The question of where accountability should rest is complex because prescrip tion drug management systems may be part of a larger organization or may be pro vided by a PBM through a contractual arrangement with a purchaser that is dis tinct from the main health plan contract. There might also be an arrangement between the two extremes of a carved-in and a carved-out program, where some of the prescription drug management activi ties are conducted by an MCO whereas others are subcontracted out to a PBM. An additional issue, closely related to the nature of the contractual arrangement for drug management systems, is the propri etary nature of much of the information associated with cost containment activities conducted on the part of PBMs. Establishment of the responsibility for reporting requirements will have implica tions for negotiations around the set of measures that must be reported and the need for sharing data.
A standardized, comprehensive set of performance indicators will enable public and private sector purchasing organiza tions to evaluate administrative and man agement functions, drug use control, cost containment, and disease management ser vices provided, as well as the impact of these activities on quality of care and con sumer satisfaction. A comprehensive set of measures also will enable these organi zations to make informed purchasing and management decisions when selecting from an array of services. Several groups have made significant progress in indicator development for a variety of activities; however, the results of these efforts have not yet led to a cohesive set of performance measures that address the broad array of services that prescription drug manage ment programs provide. The breadth and the content of the performance measure ment set will determine its utility for evalu ation and decisionmaking. This compre hensive measurement set could be includ ed within existing report cards that assess managed care plan performance or could stand alone as a separate reporting requirement.
Finally, no single entity has yet stepped forward to take on the responsibility of developing a comprehensive set of perfor mance measurement standards for evaluat ing the efficiency and effectiveness of pre scription drug management programs. Two possibilities emerge: (1) responsibili ty for such an initiative could be incorpo rated within the realm of an existing stan dards-setting organization and (2) a new body could be established. The best place for lodging that responsibility is a policy question that begs further investigation.
